NASDAQ:UPB Upstream Bio Q1 2026 Earnings Report $7.40 -0.11 (-1.46%) Closing price 04:00 PM EasternExtended Trading$7.40 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Upstream Bio EPS ResultsActual EPS-$0.75Consensus EPS -$0.73Beat/MissMissed by -$0.02One Year Ago EPSN/AUpstream Bio Revenue ResultsActual Revenue$1.03 millionExpected Revenue$1.03 millionBeat/MissBeat by +$6.00 thousandYoY Revenue GrowthN/AUpstream Bio Announcement DetailsQuarterQ1 2026Date5/13/2026TimeBefore Market OpensConference Call DateWednesday, May 13, 2026Conference Call Time7:00AM ETUpcoming EarningsUpstream Bio's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Upstream Bio Earnings HeadlinesUpstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by BrokeragesJuly 6 at 4:42 AM | americanbankingnews.comIs Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?June 25, 2026 | insidermonkey.comThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest technology bets in U.S. history. George Gilder, who has tracked technology signals for over 40 years, believes Washington just tipped its hand. He says this move points to a coming shift in computing that could leave today's machines behind - and most investors have already moved past the headline.July 6 at 1:00 AM | Eagle Publishing (Ad)10 small-cap U.S. healthcare stocks with the weakest momentum gradesJune 24, 2026 | seekingalpha.comIs Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?June 23, 2026 | insidermonkey.comUpstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First PatientsJune 19, 2026 | businesswire.comSee More Upstream Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email. Email Address About Upstream BioUpstream Bio (NASDAQ:UPB) is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges. The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages. In the immuno-oncology sphere, Upstream Bio is exploring therapeutic vaccine constructs designed to activate tumor-specific T cells, while its infectious disease programs seek to induce protective immunity against viral pathogens. By integrating translational biomarkers and adaptive clinical trial designs, the company strives to accelerate candidate selection and optimize dosing regimens. Upstream Bio operates research facilities in the United States and collaborates with academic and industry partners across several regions to advance its programs globally. The company’s leadership team comprises seasoned executives and scientists with deep expertise in virology, vaccine development and regulatory affairs. Upstream Bio is listed on the Nasdaq Global Market under the symbol UPB and continues to build strategic alliances aimed at expanding its pipeline and commercial capabilities.View Upstream Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term InvestorsMarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under PressureGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
